Moleculin Biotech wins Mexican patent for lung-targeted liposomal Annamycin through 2040
Bitget2026/09/23 12:25- Moleculin Biotech won a Mexican patent covering its lung-targeted liposomal formulation of Annamycin.
- The protection runs through Nov. 23, 2040, extending exclusivity for the technology in Mexico.
- Annamycin is being evaluated in the pivotal MIRACLE trial for relapsed or refractory acute myeloid leukemia.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
